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the negative growth regulators have been termed “gate- now-duplicated allele harbors an inactivating mutation
keepers” while those involved in DNA and chromosome or suffers methylation that shuts down its expression.
maintenance have been called “caretakers” (Kinzler and With all this said, it remains that TSGs are vitally impor-
Vogelstein, Science 280, 1036–1037, 1998); loss of either tant to understanding the molecular mechanics of can-
type of gene favors cancer. Are both types of genes cer cells. Extensive research makes it abundantly clear
real TSGs? No nomenclature czar has appeared on the that the loss of TSG function is as important to the
scene to sweep away the fog. process of cancer pathogenesis as is the gain of onco-
The narrowest reading of the term TSG says that these gene function.
genes act negatively to regulate cell proliferation and David Fischer’s anthology of reviews Tumor Suppres-
that their expression, readily detectable in a normal tis- sor Genes in Human Cancer provides an up-to-date
sue, is lost when cancer cells arise from that tissue. At view of this very active research field. By now we know
one time, it seemed that the only way to lose expression of a rather short list of TSGs whose candidacy is no
of a TSG was to inactivate it genetically in the genome longer in doubt—genes like p53, Rb, p16, PTEN, NF1,
of the developing cancer cell. But over the past five WT-1, and 2, VHL. There are other genes whose inactiva-
years, it has become evident that TSG inactivation is tion, either in the germline or somatically, accelerates
achieved equally effectively through methylation and tumorigenesis because the loss of their functions leads
resulting transcriptional repression. to hypermutable genomes; included here are BRCA1
Because the criteria governing inclusion in the TSG and 2, the mismatch repair genes, the Fanconi anemia
class are so poorly established, many “candidate TSGs” genes, the ataxia telangiectasia gene ATM, and those
have been proposed over the past decade, most of associated with xeroderma pigmentosum (XP). Yet oth-
whose candidacies remain tentative. One favored route ers still wait in a no-man’s land, promoted by some,
to validate a candidate TSG gene is to test it functionally doubted by others for one or another of the reasons
by introducing it into a tumor cell. Reexpression of bona cited above. Included here are nm-23, DCC, KA1, and
fide TSGs in a tumor cell lacking the gene is known in TSP1.
many cases to stop the proliferation of this cell, even Most of these genes are addressed in this volume,
to induce its entrance into apoptosis. With this in mind, written by authorities in these fields, and to a very great
many have introduced their favorite candidate TSGs into extent presented in highly readable, well-organized
tumor cells and observed the same outcome. The pitfall chapters. These chapters provide the vital information
here is an obvious one: most genes, independent of that nonspecialists would need to enter into this com-
their normal mode of functioning, make cells unhappy plex field. One chapter, a bit out of place in this TSG
whenever they are expressed ectopically and at non- anthology, has been written by Alex Matter of Novartis;
physiologic levels. it provides a very good overview of how the research
Yet another criterion for proving TSG status is the into the molecular biology of cancer pathogenesis is
observed progressive downregulation of expression of currently being used to identify novel drug targets and,
a gene as a tissue evolves toward a neoplastic growth in turn, the development of a new generation of rationally
state. Here the researcher skates on even thinner ice. designed anticancer therapeutics. His agenda, after all,
Some genes may be expressed by only a subset of the represents the most important end-goal of all of this
cell types present in a normal tissue (e.g., a stromal cell research—exploiting insights into cancer’s molecular
in an epithelial tissue). As a tumor develops in this tissue, causes to generate new ways of treating the disease.
the representation of the different cell types in the histo-
logically complex tumor mass changes dramatically,
and the level of certain gene products may plummet Robert A. Weinberg
because the expressing cell type is underrepresented Whitehead Institute
in the overall tumor mass. Nine Cambridge Center
Downregulation of gene expression can be equally Cambridge, Massachusetts 02142
misleading because of confusion between cause and
effect. If a bona fide TSG, operating as a master control-
ler, activates expression of dozens of downstream ef-
fectors to achieve its ends, do all of these effectors also Life and Death at the Hand
rise to the level of being TSGs? In the same vein, if a of Poly(ADP-Ribosyl)ationgrowth-promoting oncogene acts in part by shutting
down dozens of normally expressed genes, are all these
TSGs?
From DNA Damage and Stress Signaling toEven the ostensibly rigorous criteria offered by molec-
Cell Death: Poly ADP-Ribosylation Reactionsular genetics create traps. Because the second, still-
By G. De Murcia and S. Shallwild-type gene copy of a TSG is often discarded during
Oxford: Oxford University Press (2000). 238 pp. $125.00tumor progression through the process of loss of hetero-
zygosity (LOH), some TSGs have risen to prominence
simply because their chromosomal region suffers re-
Among the cell’s repertoire of posttranslational modifi-peated LOH in a series of tumors. But what if a neigh-
cations, poly(ADP-ribose) (PAR) stands out as one ofboring gene, closely linked to the candidate TSG, hap-
the most dramatic. In response to DNA damage, cellspens to be the real target of elimination by LOH? The
gold standard here has been a finding that the surviving, synthesize long polymers of ADP-ribose onto protein
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acceptors. This modification and the enzyme, poly(ADP- in the cell, including telomere replication (tankyrase) and
cellular transport (VPARP). An up-to-date comparisonribose) polymerase (PARP), responsible for its synthesis
have been the focus of intensive study for over 30 years. of the new family members is presented in chapter 2
and should serve as a good basis for what promises toDespite steady progress over the years, the path has
not been a straight one. In fact, the field has taken be an area of intensive research in the future.
So what exactly is the function of PARP-1? Few en-many twists and turns under the weight of confusing
and apparently conflicting data. Finally, the smoke has zymes have had as many papers devoted to elucidating
its function as PARP-1. The working hypothesis is simplecleared and a cohesive framework for understanding
poly(ADP-ribosyl)ation has emerged. And not a moment enough. Under normal conditions, a catalytically inactive
enzyme resides in the nucleoplasm. In response to DNAtoo soon. Indeed, with the recent renewed interest in
the field by basic researcher and pharmacologist alike, damage, PARP-1 is recruited to strand breaks. DNA
binding activates its catalytic domain, inducing auto-a monograph on the subject is timely and welcome.
PARP is a member of a superfamily of enzymes that modification. The resulting poly(ADP-ribosyl)ation at
sites of breakage promotes DNA repair. While the hy-use nicotinamide adenine dinucleotide (NAD1) as a sub-
strate to transfer ADP-ribose onto protein acceptors. pothesis was straightforward, proof that PARP-1 was
indeed required for DNA repair in vivo was not easy toWhile the mono(ADP-ribosyl) transferases, such as the
well-studied bacterial toxins, transfer a single ADP- come by. Initially (and throughout the 1980s), inhibition
of enzyme activity with NAD1 analogs was the mostribose unit to proteins, PARPs transfer multiple units
(up to 200) to generate long linear and branched chains. common approach taken to study PARP-1 function. Un-
fortunately, the inhibitors lacked the specificity neededThe ADP-ribose polymers are of a transient nature; upon
synthesis they are extensively degraded by a poly(ADP- to draw clear results and so, during the next decade
many different strategies were pursued. Chapter 3 sys-ribose) glycohydrolase (PARG). What is the purpose of
such a dramatic, transient reaction? One obvious conse- tematically details all the functional approaches taken,
including generation of PARP-1-deficient cell lines, anti-quence is to drastically alter the properties and hence
the molecular partners of the protein acceptor. A less sense strategies, overexpression of wild-type and mu-
tant PARP-1, and finally, analysis of not one, but threeapparent, but perhaps more dire, consequence for the
cell is the perturbation of NAD1 pools. Depletion of this independently derived knockout mice. The knockout
mice clinched it; when under genotoxic stress, life with-dinucleotide, by excessive synthesis of ADP-ribose
polymers, can compromise cellular energy metabolism out PARP-1 is difficult. Taken together the evidence
overwhelmingly supports a role for PARP-1 as a care-by limiting synthesis of ATP. And so the book begins
with an introduction to NAD1 as a pivotal link between taker of the genome in mammalian cells. Chapter 3 also
considers the possible molecular mechanisms of PARP-1the cell’s energy status and cellular signaling by post-
translational modification. In addition, chapter 1 intro- function (through a discussion of PARP-1-interacting
proteins) with particular emphasis on base excisionduces us to the basic players (PAR, PARP, and PARG)
as well as useful background on immunodetection and repair.
With the cell survival promoting activity of PARP-1structure of PAR. For example, an electron micrograph
displaying the remarkable branched structure of poly firmly established, the book next turns to the role of
PARP-1 in cell death. For this purpose cell death is(ADP-ribose) is worth a thousand words.
The PARP protein has been the centerpiece of the separated into two catagories: apoptosis, a genetically
controlled program, and necrosis, a more rapid, severefield for the last decade. The primary structure of this
modular, highly conserved protein indicates an amino- process that occurs in response to cell injury. Chapter
5 presents evidence indicating a pivotal role for PARP-1terminal DNA binding domain containing two zinc finger
motifs, an internal automodification region, and a car- in necrotic cell death. Remarkably, it appears that
PARP-1 can modulate cellular responses according toboxy-terminal catalytic domain. Perhaps one of the most
significant advances in the field over the last several the extent of genotoxic stress. Thus, at low levels of DNA
damage, PARP-1 promotes DNA repair, but at massiveyears is the resolution of the native structure of the
PARP catalytic domain. Chapter 2 walks us through the levels of damage (the type induced by oxidants during
reperfusion injury), overactivated PARP-1 leads to mas-structure using color plates of ribbon representations
of the catalytic domain bound to NAD1 or specific PARP sive synthesis of poly(ADP-ribose). This synthesis rap-
idly depletes cellular NAD1 and consequently ATP, lead-inhibitors. Scrutiny of the structure against the backdrop
of numerous in vitro studies of PARP mutants allows a ing to an energy crisis that culminates in necrotic cell
death. Here the PARP-1 knockout mice have reallyclear and concise picture of the enzymatic properties
of this protein. earned their keep. Lack of PARP-1 confers protection to
a wide range of insults including stroke and myocardialIn 1996, when the crystal structure first appeared, it
confirmed PARP as a member of the superfamily of ischemia-reperfusion. These results can be reproduced
in animals by treating with pharmacological inhibitors ofADP-ribosyl transferases. At that time, PARP was the
sole member of the unique subclass of poly(ADP- PARP-1, opening the door to new therapeutic strategies.
While a role for PARP-1 in necrotic cell death is wellribosyl) transferases. Remarkably, over the last few
years, four new genes encoding PARPs have been dis- supported by animal models and inhibitor studies, the
function of PARP-1 in apoptosis is less clear. Duringcovered. This newly discovered PARP family contains the
original PARP (now renamed PARP-1), PARP-2, PARP-3, apoptosis cellular components are dismantled in an or-
derly fashion. This process includes cleavage of specificVPARP, and tankyrase. Unexpectedly, whereas some
of the new PARPs, such as PARP-2, may function in proteins by proteases termed caspases and degrada-
tion of DNA into small fragments. It has been known forgenome protection, others appear to play different roles
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some time that PARP-1 is one of the first substrates to used throughout the book are particularly useful. Even
be cleaved by caspases during apoptosis. This cleavage though each chapter has a different set of authors, there
separates the DNA binding and catalytic domains, ren- is minimal repetition and plenty of cross referencing
dering on one hand a protein fragment that can bind DNA throughout.
breaks constituitively and on the other hand a catalytic As stated in the last paragraph of the book “poly(ADP-
fragment that can no longer be activated by DNA breaks. ribose) polymerase was for many years after its discov-
As outlined in chapter 4, studies using inhibitors or ery a biochemical curiosity” (p. 226). Not anymore. A
knockout mice have yielded conflicting results on the clear role for PARP-1 has now been established in the
role of PARP-1 in apoptosis. However, just the existence maintenance of genome integrity and cell death. And
of normal fertile mice rules out a critical role for PARP-1 that’s just the beginning. The discovery of a multigene
in apoptosis during development and makes it unlikely PARP family implicated in a wide variety of biological
that PARP-1 is an essential component of the cell death processes indicates that poly(ADP-ribosyl)ation will be a
pathway. Why then is PARP-1 cleavage one of the earli- widespread form of posttranslational modification used
est events in apoptosis? The emerging model is that throughout the cell. In fact, don’t be surprised if you
inactivation of PARP-1 nullifies its survival function unexpectedly bump into a PARP while working in an
allowing a timely completion of the apoptotic program. apparently unrelated area of research. And if you do,
Inactivation of PARP-1 prevents massive induction (by you will be happy to have this book in hand.
apoptotic DNA fragments) of poly(ADP-ribosyl)ation that
could lead to necrosis. In addition, the cleaved DNA Susan Smith
binding domain of PARP-1 may bind irreversibly to apo- Skirball Institute of Biomolecular Medicine
ptotic DNA fragments, preventing futile DNA repair. New York University School of Medicine
By the time we arrive at chapter 6, which describes 540 First Avenue, 2nd Floor
PARP inhibitors, the reason for the recent surge of inter- New York, New York 10016
est in PARPs by the pharmaceutical industry is evident.
The role of PARP-1 along a continuum from cell survival
to cell death makes possible a broad range of clinical
strategies. For example, at one end of the spectrum is Chromatin and Transcription:
the DNA repair-survival function. Here, PARP-1 inhibi- Merging Package and Processtors can be used to block DNA repair and hence increase
cytotoxicity of specific classes of anti-cancer therapies.
At the other end of the spectrum lies the necrosis-cell
Chromatin Structure and Gene Expression,death function. In this case PARP-1 inhibitors may im-
Second Editionpart a protective effect by blocking the necrotic cell
Edited by Sarah C.R. Elgindeath pathway implicated in tissue damage induced
and Jerry L. Workmanby ischemia and reperfusion. Chapter 6 describes the
Oxford: Oxford University Press (2001). 328 pp. $60.00history of PARP inhibitors as well as new strategies and
novel approaches. Of course, the crystal structure will
be of great use for designing new inhibitors and the
Few active scientists can legitimately claim to rememberPARP-1 knockout mice will be valuable in distinguishing
the days when conventional wisdom held that deoxyri-toxic side effects of the inhibitor that may be unrelated
bonucleic acid was far too simple a chemical to embodyto PARP-1. An important issue (which may be critical in
genetic information. We now smile knowingly at theclinical strategies and extremely useful for basic re-
quaint arguments that the four “letters” in the DNA al-search studies) will be whether one can generate inhibi-
phabet could hardly suffice to encode the vast range oftors that distinguish between PARP family members.
genetic characteristics inherent in any individual organ-The final chapter considers the role of PARP-1 as a
ism, in the differences between organisms of a species,participant in a DNA damage signaling cascade. For
and among the myriad species of our biotic world. Theexample, once DNA damage is sensed how is it trans-
successful modeling of the structure of DNA led to theduced to signal cell cycle arrest or apoptosis? PARP-1’s
solution of the coding problem and eventually to theproperties are well suited to cell signaling. It can detect
unraveling of the mechanisms of replication, transcrip-DNA damage and, through poly(ADP-ribosyl)ation, trans-
tion, and translation that accomplish the copying andlate and amplify the damage signal. The chapter explores
reading of the genetic code.the relationship between PARP-1 and other known com-
Not so rare are scientists who can recall a similarponents of DNA damage signaling pathways such as
opprobrium being laid to chromatin. Even in early days,DNA-PK, ATM, p53, and the transcription factor NFkB.
it was recognized that something had to package someUnderstanding the molecular mechanisms that underlie
2 meters of linear DNA to fit within the 10 mm diameterthe DNA damage signaling cascade will obviously be a
of a human cell nucleus. The obviously redundantmain focus of future research. Undoubtedly PARPs will
structure of the nucleosome (and the higher orders offigure largely, but at the moment, exactly how remains
chromatin structure, up to the compacted mitotic chro-a matter of speculation.
mosomes) might certainly help to accomplish this pack-The book succeeds in the daunting task of pulling
aging. But the genetic regulatory role of this packagingtogether a plethora of papers from the last two decades
has at times been viewed as no more than an obviousinto a cohesive review of the field. Great efforts are
steric hindrance to those elegant processes notedmade to critically review and reconcile areas of conflict-
ing data. The charts, tables, and schematic diagrams above.
